Pipeline

Five things for pharma marketers to know: Thursday, October 12, 2017

Five things for pharma marketers to know: Thursday, October 12, 2017

By

Merck scraps plans for cholesterol drug; oncologist describes how he tells people about his work; researchers question list of side effects in DTC ads

Infographic | How often are drugmakers sharing clinical-trial data?

Infographic | How often are drugmakers sharing clinical-trial data?

The answer: it depends on what phase the trial is in.

Five things for pharma marketers to know: Tuesday, September 12, 2017

Five things for pharma marketers to know: Tuesday, September 12, 2017

By

Alexion to cut 600 jobs; Sage Therapeutics' experimental seizure drug fails to meet expectations; Apple is interested in medical and health activity

Can marketing techniques save clinical trials?

Can marketing techniques save clinical trials?

By

No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.

Why Sanofi's dengue fever vaccine fell short of expectations

Why Sanofi's dengue fever vaccine fell short of expectations

By

Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

By

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Merck, Novartis pipeline stunners headline surprisingly good month for CV agents

Merck, Novartis pipeline stunners headline surprisingly good month for CV agents

By

Merck's CETP inhibitor anacetrapib and Novartis' monoclonal antibody ACZ885 hit their primary goals in late-stage cardiovascular outcomes trials, both unexpectedly positive results that are heating up this category.

Five things for pharma marketers to know: Tuesday, June 27, 2017

Five things for pharma marketers to know: Tuesday, June 27, 2017

By

Merck announces positive trial results for CETP inhibitor; Purdue Pharma defends withholding of OxyContin marketing material; Roche's experimental haemophilia drug significantly cuts bleed rate

Five things for pharma marketers to know: Monday, June 12, 2017

Five things for pharma marketers to know: Monday, June 12, 2017

By

Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative

Sunday at ASCO: What the latest trial data has to say about precision medicine

Sunday at ASCO: What the latest trial data has to say about precision medicine

By

Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs

Saturday at ASCO: Trial results reveal promising data for combo I-O drugs but no home runs

By

Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.

The immuno-oncology market prepares for the inevitable question: 'What's next?'

The immuno-oncology market prepares for the inevitable question: 'What's next?'

By

This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck's Keytruda and Bristol-Myers Squibb's Opdivo, in combination or alone.

Five things for pharma marketers to know: Friday, May 26, 2017

Five things for pharma marketers to know: Friday, May 26, 2017

By

FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes

Five things for pharma marketers to know: Tuesday, May 23, 2017

Five things for pharma marketers to know: Tuesday, May 23, 2017

By

Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug

Five things for pharma marketers to know: Wednesday, May 17, 2017

Five things for pharma marketers to know: Wednesday, May 17, 2017

By

FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations

Five things for pharma marketers to know: Thursday, May 11, 2017

Five things for pharma marketers to know: Thursday, May 11, 2017

By

FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs

MedImmune goes after challenging lupus market

MedImmune goes after challenging lupus market

By

While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.

Five things for pharma marketers to know: Monday, April 10, 2017

Five things for pharma marketers to know: Monday, April 10, 2017

By

Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose

Five things for pharma marketers to know: Thursday, April 6, 2017

Five things for pharma marketers to know: Thursday, April 6, 2017

By

The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers

Five things for pharma marketers to know: Monday, April 3, 2017

Five things for pharma marketers to know: Monday, April 3, 2017

By

Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

By

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

By

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Novartis aims to bring first oral asthma drug to market in two decades

Novartis aims to bring first oral asthma drug to market in two decades

By

An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

Study finds Repatha reduces risk of heart attack, stroke, but cost concerns remain

By

Amgen said it would offer payers a refund for patients who have a heart attack or stroke while taking the PCSK9 inhibitor.

Five things for pharma marketers to know: Friday, March 17, 2017

Five things for pharma marketers to know: Friday, March 17, 2017

By

The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug

Five things for pharma marketers to know: Tuesday, March 14, 2017

Five things for pharma marketers to know: Tuesday, March 14, 2017

By

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Five things for pharma marketers to know: Monday, March 6, 2017

Five things for pharma marketers to know: Monday, March 6, 2017

By

Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema

When It Comes to the FDA, Does It All Come Down to Money?

When It Comes to the FDA, Does It All Come Down to Money?

In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?

Five things for pharma marketers to know: Thursday, March 2, 2017

Five things for pharma marketers to know: Thursday, March 2, 2017

By

Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

By By

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena